| Name | Title | Contact Details |
|---|
Peppy is the digital health health app that supports menopause, fertility, mens health, womens health and more with real health experts.
Allphase Clinical Research Services Inc. is a Ottawa, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clay County Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Clay Center, KS. To find more information about Clay County Medical Center, please visit www.ccmcks.org
Health Republic Insurance of New York is a not-for-profit health insurance CO-OP (Consumer Operated and Oriented Plan) established under the Affordable Care Act to expand affordable healthcare options for all New Yorkers. Our high-quality plans are available to individuals and small groups, both on exchange and off, throughout the state. Since we opened our doors in October of 2013, we`ve enrolled over 145,000 members, making us the largest health insurance cooperative in the country and one of the fastest growing insurance companies in New York history. Our tremendous success is a testament to the way our values resonate with our members.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."